Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway
A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight over 72 weeks
International Journal of Molecular Medicine , 20(2), 91-97
However, weight loss is still affected by the full body system, including metabolism, hormones, muscle mass, sleep, stress and other health conditions
Related Comparisons Retatrutide vs Tirzepatide Retatrutide, a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, demonstrates unprecedented weight loss efficacy in clinical trialsup to 24.2% body weight reduction at 48 weeks
US$ 27.76
US$ 28.69
US$ 24.05
US$ 20.15
US$ 25.58
US$ 25.07
